Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00 at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target boosted by JPMorgan Chase & Co. from $39.00 to $41.00 in a research report released on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also recently weighed in on SNDX. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Trading Up 7.5 %

NASDAQ:SNDX opened at $14.10 on Thursday. The stock has a market cap of $1.21 billion, a P/E ratio of -3.88 and a beta of 0.92. The stock has a 50 day simple moving average of $14.23 and a 200 day simple moving average of $16.16. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, sell-side analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Activity

In other news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares in the company, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd bought a new stake in Syndax Pharmaceuticals during the 4th quarter worth $26,000. Quantbot Technologies LP bought a new stake in Syndax Pharmaceuticals during the 3rd quarter worth $49,000. Virtus ETF Advisers LLC grew its position in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after acquiring an additional 827 shares during the last quarter. Cape Investment Advisory Inc. grew its position in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after acquiring an additional 3,927 shares during the last quarter. Finally, KBC Group NV lifted its holdings in Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after buying an additional 3,559 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).